Ipamorelin

Ipamorelin research peptide primarily binds to the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor, located in the pituitary and hypothalamus, triggering a signaling cascade that increases intracellular cAMP, reduces somatostatin inhibition, and promotes selective, pulsatile GH release from somatotroph cells. Additionally, laboratory models reveal downstream enhancements in IGF-1 levels, protein synthesis, and metabolic shifts, including potential support for lean mass preservation and bone remodeling through GH/IGF-1 axis activation. These actions, observed in rat pituitary cell assays, swine models, and human pharmacokinetic studies, contribute to observed improvements in GH pulsatility and endocrine balance, with recent research emphasizing its reassuring profile for targeted, physiologically relevant GH modulation in models of growth, aging, and catabolic states.

• Growth hormone secretagogue receptor activation investigations

• Pulsatile GH release and selectivity mechanism analysis

• IGF-1 signaling and protein synthesis pathway studies

• Body composition and lean mass preservation evaluation

• s Bone mineral content and longitudinal growth research

• Endocrine specificity and minimal cortisol impact examinations

• Raun K et al. Eur J Endocrinol. 1998;139(5):552-561
• Johansen PB et al. Growth Horm IGF Res. 1999;9(6):411-418
• Beck DE et al. Dis Colon Rectum. 2008;51(8):1181-1189
• Hansen TK et al. J Clin Endocrinol Metab. 2002;87(3):1041-1044
• Gobburu JV et al. J Pharmacol Exp Ther. 1999;291(3):1275-1283